Adicet Bio, Inc.

DB:1IJA Stock Report

Market Cap: €70.7m

Adicet Bio Valuation

Is 1IJA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1IJA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1IJA (€0.81) is trading below our estimate of fair value (€20.41)

Significantly Below Fair Value: 1IJA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1IJA?

Key metric: As 1IJA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1IJA. This is calculated by dividing 1IJA's market cap by their current book value.
What is 1IJA's PB Ratio?
PB Ratio0.4x
BookUS$211.53m
Market CapUS$74.16m

Price to Book Ratio vs Peers

How does 1IJA's PB Ratio compare to its peers?

The above table shows the PB ratio for 1IJA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average13.1x
VSC 4SC
47.4xn/a€48.2m
MDG1 Medigene
1.1x-4.1%€22.5m
HPHA Heidelberg Pharma
2.8x-33.0%€102.1m
2INV 2invest
1xn/a€62.7m
1IJA Adicet Bio
0.4x6.7%€74.2m

Price-To-Book vs Peers: 1IJA is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (13.1x).

Price to Book Ratio vs Industry

How does 1IJA's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
1IJA 0.4xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1IJA is good value based on its Price-To-Book Ratio (0.4x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 1IJA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1IJA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1IJA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1IJA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.81
€5.93
+632.3%
25.4%€7.41€3.70n/a5
Nov ’25€1.15
€5.75
+402.0%
25.4%€7.18€3.59n/a5
Oct ’25€1.23
€5.75
+367.7%
25.4%€7.18€3.59n/a5
Sep ’25€1.27
€8.18
+542.9%
52.9%€17.28€4.55n/a6
Aug ’25€1.33
€8.28
+521.4%
52.9%€17.47€4.60n/a6
Jul ’25€1.06
€8.28
+680.9%
52.9%€17.47€4.60n/a6
Jun ’25€1.30
€8.28
+535.2%
52.9%€17.47€4.60n/a6
May ’25€1.42
€8.92
+527.9%
52.1%€17.65€4.64n/a5
Apr ’25€2.15
€8.79
+309.6%
52.1%€17.40€4.58n/a5
Mar ’25€2.11
€8.89
+320.6%
52.1%€17.60€4.63n/a5
Feb ’25€2.71
€11.70
+332.5%
64.7%€23.76€4.57n/a5
Jan ’25€1.51
€14.19
+840.8%
59.2%€24.45€4.53n/a6
Dec ’24€1.02
€13.13
+1,190.1%
64.6%€24.82€4.60n/a7
Nov ’24€1.15
€17.06
+1,381.1%
44.8%€26.12€5.60€1.157
Oct ’24€1.31
€17.06
+1,200.9%
44.8%€26.12€5.60€1.237
Sep ’24€1.73
€16.70
+865.0%
44.8%€25.58€5.48€1.277
Aug ’24€2.35
€19.55
+732.5%
45.4%€34.66€5.47€1.337
Jul ’24€2.20
€19.55
+787.7%
45.4%€34.66€5.47€1.067
Jun ’24€4.64
€23.65
+409.9%
35.0%€35.32€5.58€1.309
May ’24€5.25
€24.50
+366.7%
22.8%€34.49€17.24€1.429
Apr ’24€5.30
€24.81
+368.2%
22.4%€35.45€17.72€2.1510
Mar ’24€7.30
€26.15
+258.2%
19.1%€36.00€18.95€2.1110
Feb ’24€8.30
€26.15
+215.0%
19.1%€36.00€18.95€2.7110
Jan ’24€7.90
€27.34
+246.1%
16.5%€36.07€19.94€1.5110
Dec ’23€17.50
€27.42
+56.7%
14.4%€32.82€20.27€1.0210
Nov ’23€17.00
€28.32
+66.6%
14.9%€34.51€21.32€1.1510

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$16.05

7D

4.9%

1Y

79.5%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

7D

0.4%

1Y

-33.2%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$28.60

7D

2.1%

1Y

21.2%